FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number 3235-0287 Estimated average burden hours per response: 0.5

D

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] Biller Scott				2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS INC [AGIO]								(Ch	eck all app Direct	ationship of Reporting I c all applicable) Director Officer (give title below) <u>Chief Scientin</u>		10% C		
(Last) (First) (Middle) C/O AGIOS PHARMACEUTICALS, INC.				3. Date of Earliest Transaction (Month/Day/Year) 01/26/2017								X below	below)					
88 SIDNEY STREET				4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) CAMBR			02139												filed by Mor		porting Pers an One Rep	
(City)	(5		Zip) lel-N	on-Deriv	ative \$	Secur	ities Ac	quired,	Dis	oosed o	of, or E	Bene	ficial	ly Owne	d			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day					Execu if any	eemed tion Date, h/Day/Yea	Transaction Dispe Code (Instr. and 5			urities Acquired (A sed Of (D) (Instr. 3,) (A) or Dat			r 5. Amo Securit Benefit Owned Follow Report	ies cially ing	For (D) Indi	Ownership m: Direct or irect (I) str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	V	Amoun	Amount (A) o (D)		Price	Transa	action(s) 3 and 4)			
		Т	able II	- Derivat (e.g., p				uired, D s, option	•					Owned				
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any		4. Transact Code (In 8)	tion of nstr. D A (A D of (II	Number f erivative ecurities cquired (or isposed f (D) nstr. 3, 4 nd 5)	6. Date Ex Expiration (Month/D	•	d 7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership			

or Number Date Expiration of v (A) (D) Exercisable Title Code Date Shares Common Commor \$9.05 01/26/2017 34,090 (1) 04/29/2023 34,090 \$0.00 54,090 A (right to stock

Explanation of Responses:

1. This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares.

Remarks:

stock

buy)

<u>/s/ Andrew Hirsch, as</u>	01/07/2017
<u>Attorney-in-Fact for Scott</u> <u>Biller</u>	01/27/2017
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.